Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

A Power Boost for COVID-19 Clinical Trials

More than 3,000 COVID-19 clinical trials have launched in the past year. That sounds like good news, but many of these are ill-suited for identifying interventions that save lives. Bloomberg School researchers have responded with strategies that can better distinguish clinically meaningful signals from confounding statistical noise.

Many COVID-19 trials have too small a sample size, and thus lack the “statistical power” to confidently determine whether patients are responding to treatment, says Elizabeth Ogburn, an associate professor in the Department of Biostatistics. Such underpowered trials may not have enough participants to produce a measurable effect from therapy; they may also yield false-positive results if a few patients’ conditions improve by chance rather than in response to treatment.